Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product

An announcement from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) is now available.

Qyuns Therapeutics has subscribed to a principal-guaranteed, floating-yield wealth management product from a commercial bank, investing RMB100 million of its idle funds with a maturity date of September 23, 2026. The product offers a guaranteed annual yield of 0.95% with potential floating returns up to 1.25%, and has been assessed as low risk under the bank’s internal criteria.

The company funded the subscription with its own resources, excluding IPO proceeds, and framed the move as part of its capital management strategy to secure better returns than standard bank deposits while maintaining liquidity and low risk. The board emphasized that internal controls are in place to ensure the investment does not affect working capital or operations, and that the transaction qualifies as a discloseable transaction under Hong Kong listing rules due to its size, triggering notification and announcement requirements for investors.

The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.

More about Qyuns Therapeutics Co., Ltd. Class H

Qyuns Therapeutics Co., Ltd. is a China-based biotech company listed on the Hong Kong Stock Exchange, specializing in biologic therapies for autoimmune and allergic diseases. Its self-developed pipeline targets skin, rheumatic, respiratory and digestive conditions, supported by commercial-scale in-house manufacturing capabilities that underpin its growth ambitions in these therapeutic areas.

Average Trading Volume: 245,553

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.05B

Find detailed analytics on 2509 stock on TipRanks’ Stock Analysis page.